Epilepsy treatment in neuro-oncology: A rationale for drug choice in common clinical scenarios

dc.contributor.author	Sánchez-Villalobos, José-Manuel
dc.contributor.author	Aledo-Serrano, Ángel
dc.contributor.author	Villegas-Martínez, Irene
dc.contributor.author	Shaikh, Mohd-Farooq
dc.contributor.author	Alcaraz, Miguel
dc.date.accessioned	2025-11-21T08:48:40Z
dc.date.available	2025-11-21T08:48:40Z
dc.date.issued	2022
dc.identifier.citation	Sánchez-Villalobos JM, Aledo-Serrano Á, Villegas-Martínez I, Shaikh MF, Alcaraz M. Epilepsy treatment in neuro-oncology: A rationale for drug choice in common clinical scenarios. Front Pharmacol. 6 de octubre de 2022;13:991244.
dc.identifier.issn	0302-9743
dc.identifier.uri	https://sms.carm.es/ricsmur/handle/123456789/22045
dc.language.iso	eng
dc.publisher	Frontiers Media S.A.
dc.rights	Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internacional
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/es/	*
dc.title	Epilepsy treatment in neuro-oncology: A rationale for drug choice in common clinical scenarios
dc.type	info:eu-repo/semantics/article
dc.relation.publisherversion	https://www.frontiersin.org/articles/10.3389/fphar.2022.991244/full
dc.identifier.doi	10.3389/fphar.2022.991244
dc.journal.title	Frontiers in Pharmacology
dc.identifier.essn	1611-3349